No Customer Above Ten PercentWide moat

Intuitive Surgical (ISRG) — moat facet

Diversified by name and identical by exposure — thousands of hospitals funded by a handful of payers.

Intuitive discloses no customer concentration, and the structure of its business explains why. The installed base was approximately 11,710 da Vinci systems and 1,096 Ion systems at 30 June 20261, spread across hospitals and health systems in the United States, Europe, Japan, Korea, China, India, Taiwan, Canada and dozens of distributor markets2.

Accounts receivable ($M)$1,225.4MEnd 2024$1,527.3MEnd 2025US 68% of 2025 revenue against 32% outside it; OUS procedures grew about 23% against 15%.
No customer reaches ten percent, in any year. The credit exposure is as diffuse as the revenue, which is genuinely rare in this collection.

The commercial consequence is that no individual buyer has leverage. A hospital cannot threaten to move its volume, because the instruments only fit Intuitive's arms and the surgeons are trained on Intuitive's console. There is no annual tender, no rebate schedule and no key-account negotiation of the kind that governs most hospital purchasing.

Geographic concentration is modest by the standards of this collection: 68% domestic and 32% outside the United States in 2025, moving slowly toward the latter — outside-the-US procedures grew 23% against 15% domestically3, and the company says it expects OUS to become a greater share over time.

The credit exposure is worth noting because it has grown. Intuitive now finances a large part of its own installed base through leases, and warns that "our exposure to the credit risks relating to our lease financing arrangements may increase if our customers are adversely affected by economic pressures or uncertainty, changes in healthcare laws, coverage and reimbursement, or other customer-specific factors"4. Accounts receivable rose to $1,527.3 million at the end of 2025 from $1,225.4 million5.

What the diversification does not do is diversify demand. Every one of those thousands of hospitals gets its money from a handful of payers per country, and those payers change their rules together.

Set the customer count against payer concentration. There is no number for the second, which is exactly the problem: the exposure that matters is the one Intuitive cannot disclose because it has no counterparty.

Moat trajectory: Holding steady

Intuitive has disclosed no customer at ten percent of revenue for years and the installed base keeps broadening. Genuine diversification, holding steady.

The number that tests this moat
Reported
U.S. share of revenue
68% in 2025 - $6,815.8M of $10,064.7M, from 66% in 2023

No hospital is a large customer, but most of the revenue depends on one country's payers. A rising U.S. share concentrates the business further on the coverage decisions made in Washington.

Source: Intuitive Surgical Form 10-K, FY2025 ↗
References
  1. ReportedThe installed base was approximately 11,710 da Vinci systems and 1,096 Ion systems at 30 June 2026, spread across hospitals and health systems in the United States, Europe, Japan, Korea, China, India, Taiwan, Canada and dozens of...
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  2. ReportedThe installed base was approximately 11,710 da Vinci systems and 1,096 Ion systems at 30 June 2026, spread across hospitals and health systems in the United States, Europe, Japan, Korea, China, India, Taiwan, Canada and dozens of...
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  3. ReportedGeographic concentration is modest by the standards of this collection: 68% domestic and 32% outside the United States in 2025, moving slowly toward the latter — outside-the-US procedures grew 23% against 15% domestically, and the company...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  4. ReportedIntuitive now finances a large part of its own installed base through leases, and warns that "our exposure to the credit risks relating to our lease financing arrangements may increase if our customers are adversely affected by economic...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
  5. ReportedAccounts receivable rose to $1,527.3 million at the end of 2025 from $1,225.4 million.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - consolidated financial statements and notes (balance sheet, cash and investments, property and equipment, lease arrangements, revenue disaggregation by geography, accounts receivable, share-based compensation and share counts) — FY2025 · publ. February 3, 2026 · source ↗
Sources
Generated September 23, 2026